Akebia Therapeutics, Inc. (NASDAQ:AKBA) headquartered in Cambridge, will host a conference call for the investment community to discuss the 3Q20 earnings result on 5th November 2020 at 9:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.akebia.com
Earnings Expectation
Akebia Therapeutics, Inc. is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.17 per share from revenue of $ 84.90 million. Looking ahead, the full year loss are expected at $ 2.33 per share on the revenues of $ 324.22 million.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co.
